Symptomatic atherosclerosis is associated with an altered gut metagenome by Karlsson, Fredrik H. et al.
ARTICLE
Received 24 Sep 2012 | Accepted 7 Nov 2012 | Published 4 Dec 2012
Symptomatic atherosclerosis is associated
with an altered gut metagenome
Fredrik H. Karlsson1, Frida Fåk2,3,*, Intawat Nookaew1,*, Valentina Tremaroli2,3, Bjo¨rn Fagerberg2,3,
Dina Petranovic1, Fredrik Ba¨ckhed2,3 & Jens Nielsen1
Recent ﬁndings have implicated the gut microbiota as a contributor of metabolic diseases
through the modulation of host metabolism and inﬂammation. Atherosclerosis is associated
with lipid accumulation and inﬂammation in the arterial wall, and bacteria have been
suggested as a causative agent of this disease. Here we use shotgun sequencing of the gut
metagenome to demonstrate that the genus Collinsella was enriched in patients with
symptomatic atherosclerosis, deﬁned as stenotic atherosclerotic plaques in the carotid artery
leading to cerebrovascular events, whereas Roseburia and Eubacterium were enriched in
healthy controls. Further characterization of the functional capacity of the metagenomes
revealed that patient gut metagenomes were enriched in genes encoding peptidoglycan
synthesis and depleted in phytoene dehydrogenase; patients also had reduced serum levels of
b-carotene. Our ﬁndings suggest that the gut metagenome is associated with the
inﬂammatory status of the host and patients with symptomatic atherosclerosis harbor
characteristic changes in the gut metagenome.
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T
he gut metagenome has been implicated as an environ-
mental factor inﬂuencing adiposity and obesity by
modulating host lipid metabolism1–4. The gut microbiota
is also a source of inﬂammatory molecules such as
lipopolysaccharide and peptidoglycan that may contribute to
metabolic disease2,5,6. Whole-genome metagenomic sequencing
has provided knowledge about the structure of the human gut
microbiome and identiﬁed a large number of genes and direct
links to functional information7,8. Links between the gut
metagenome and human diseases have been investigated,
showing that obesity is associated with alterations in the gut
metagenome and reduced bacterial diversity9. Going beyond
traditional comparative analysis of functional components, the
integration of metagenomic data with metabolic network analysis
provides deeper understanding of metabolic capabilities of the
metagenome10, and this approach could be very useful for
mechanistically delineating the link between the gut metagenome
and human health.
Atherosclerotic disease, with manifestations such as myocardial
infarction and stroke, is characterized by accumulation of
cholesterol and recruitment of macrophages to the arterial wall.
The gut microbiota has been shown to metabolize the dietary
lipid phosphatidylcholine to trimethyl amine, which promotes
atherosclerosis and inﬂammation in mice, furthermore levels of
choline, trimethylamine N-oxide and betaine have been found to
predict cardiovascular disease (CVD) risk in humans11. In a
recent study, we pyrosequenced the 16S rRNA gene and showed
that atherosclerotic plaques contain bacterial DNA with
phylotypes common to the gut microbiota and that the amount
of bacterial DNA in the plaque correlated with inﬂammation12.
However, it is unclear whether atherosclerosis is associated with
alterations in the composition of the gut metagenome.
To address this issue, we sequenced the gut metagenomes of
patients with symptomatic atherosclerotic plaques and gender-
and age-matched controls without large vulnerable plaques in
the carotid arteries. To analyse the data, we developed and
used a bioinformatics pipeline, Metagenomic Data Utilization
and Analysis, (MEDUSA) that, besides identiﬁcation of species
abundance, also allows for de novo assembly and the identiﬁca-
tion of enriched metabolic functions in the metagenome. Our
data show that patients were enriched in the genus Collinsella
whereas controls were enriched in Eubacterium and Roseburia. At
the functional level, patient metagenomes were enriched in genes
encoding peptidoglycan biosynthesis whereas those of healthy
controls were enriched in phytoene dehydrogenase genes.
Results
Taxonomic characterization of the gut microbiota. To address
whether the gut metagenome is associated with symptomatic
atherosclerosis, we sequenced the fecal metagenome of 12
patients with symptomatic atherosclerotic plaques (who had
undergone carotid endarterectomy for minor ischemic stroke,
transient ischemic attack or amaurosis fugax) and 13 gender- and
age-matched controls without large vulnerable plaques in the
carotid arteries (Table 1). In total, we generated 337 million
100 bp paired-end reads (12.5±4.7 (s.d.) million reads per
sample) that, ﬁrst, were trimmed and ﬁltered to only contain
non-human reads longer than 35 bp (Fig. 1a). To determine the
composition of the gut microbiota, we aligned the reads to a
catalog of 2,382 non-redundant reference genomes (Supple-
mentary Data 1) collected from National Center for Biological
Information (NCBI) and Human Microbiome Project catalog
(http://hmpdacc.org). On average, 28% of the reads in a sample
could be aligned to any reference genome, which is close to the
31% found in a previous metagenomic study using Illumina
reads7. The majority (98±4% (s.d.) of aligned reads were
bacterial and dominated by the phyla Firmicutes and
Bacteroides, representing 56% and 29% of the microbiota,
respectively, followed by Actinobacteria (6%) and
Proteobacteria (4%; Supplementary Fig. S1). This distribution is
in agreement with previous observations13–14. The archael
Table 1 | Characteristics of study participants.
Controls (n¼ 13) Patients (n¼ 12) P-value C vs P Excluded controls (n¼2)
Males (n) 10 9 1* 2
Age (years) 70.5 (0.5) 67.6 (8.6) 0.27w 71(0)
Current smoker (n) 0 4 0.04* 0
Hypertension (n) 2 10 0.001* 0
Diabetes (n) 0 3 0.09* 0
Previous myocardial infarction (n) 0 3 0.09* 0
Statin treatment (n) 0 9 o0.001* 0
Aspirin 0 12 o0.001* 0
Cerebrovascular event o0.001*
Minor brain infarction (n) 0 5 0.01* 0
Transient ischemic symptoms (n) 0 4 0.04* 0
Retinal artery (n) 0 3 0.09* 0
BMI, kgm 2 23.7 (2.9)z 25.8 (2.4)y 0.08w 25.6 (8.8)
Cholesterol (mmol l 1) 5.59 (1.20) 4.62 (1.59) 0.10w 5.38 (0.62)
Triglycerides (mmol l 1) 1.19 (0.74) 1.72 (1.08) 0.048 1.8 (0.77)
HDL cholesterol (mmol l 1) 1.67 (0.44) 1.32 (0.26) 0.026w 1.49 (0.63)
LDL cholesterol (mmol l 1) 3.39 (1.05) 2.53 (1.44) 0.10w 3.07 (0.91)
ApoA1 1.44 (0.20) 1.33 (0.21) 0.22w 1.46 (1.48)
ApoB 1.09 (0.29) 0.95 (0.34) 0.27w 1.16 (0.42)
WBC 5.47 (1.06)y 7.78 (1.56)z o0.001w 5.05 (1.77)
hsCRP (mg l 1) 2.14 (3.35) 4.81 (5.95) 0.128 1.81 (2.27)
BMI, body mass index; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; WBC, white blood cell count.
Data are mean (s.d.) unless otherwise indicated.
*Fisher’s exact test.
wWelch’s t-test.
zn¼ 11.
yn¼ 10.
8Wilcoxon rank-sum test.
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phylum Euryarchaeota was also present but with a high inter-
subject variation (2.0±4.3% (s.d.); Supplementary Fig. S1) and
was dominated by the species Methanobrevibacter smithii, which
constituted at least 93% of the reads assigned to Euryarchaeota in
any individual. Bacteroides, Ruminococcus, Eubacterium and
Faecalibacterium were the most abundant genera in our cohort
(Supplementary Fig. S2) as found previously7,13. Species and
genome level abundances were also calculated (Supplementary
Figs S3 and S4), and Faecalibacterium prausnitzii was shown to
be the most abundant species. At coverage of at least 1% of
aligned reads to reference genomes, we identiﬁed 82 species in all
27 subjects making up the core microbiota in our cohort
(Supplementary Data 2). By contrast, the MetaHIT study
identiﬁed 18 species in their total cohort of 124 individuals and
75 in half of the individuals at 1% coverage7. This difference may
be explained by the fact that our cohort was smaller and more
homogenous (that is, individuals of a similar age living in the
same area) than the MetaHIT cohort, which included healthy
subjects as well as patients with obesity or inﬂammatory bowel
disease from different countries.
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Figure 1 | Microbial composition associated with symptomatic atherosclerosis. (a) Illustration of our bioinformatics pipeline for analysing metagenome
data to elucidate its relation to human metabolic disease. Sequence reads from the gut metagenome were generated with high-throughput sequencing
technology and subjected to quality control. High-quality reads were used for alignment to reference genomes to estimate species abundance. De novo
assembly of the metagenome allows for discovery of new genes not yet found in databases. Annotation of genes to KEGG allows for integration of
information at the gene level with the metabolic network. Data on plasma metabolites and proteins together with gut metagenomic data constitute a basis
for discovery of mechanisms for gut metagenome association with etiology of complex diseases. (b) Principal component analysis of microbial species
abundance using health status as instrumental variable. Red is patients (P, n¼ 12), green controls (C, n¼ 13). The relation between microbial abundance
and health status was assessed with Monte Carlo simulations with 10,000 replications by which a P-value was calculated. (c) Abundance of bacterial
genera and species that differ between patients (n¼ 12) with symptomatic atherosclerosis (P) and controls (n¼ 13) (C). Adj. Po0.05 for all. (d) Bacterial
genera correlating with biomarkers of atherosclerosis, using Spearman’s correlation. All samples, including the two excluded controls (see methods for
details), were used for correlations with triglycerides, CRP (n¼ 27, respectively) and white blood cell count (WBC; n¼ 23). Only controls were used for
low-density lipoprotein (LDL), high-density lipoprotein (HDL) and cholesterol correlations to avoid interactions with possible drug effects (n¼ 15). *Adj.
Po0.05, **adj. Po0.01 and ***adj. Po0.001. Boxes denote the interquartile range (IQR) between the ﬁrst and third quartiles and the line within denotes
the median; whiskers denote the lowest and highest values within 1.5 times IQR from the ﬁrst and third quartiles, respectively. Circles denote data points
beyond the whiskers.
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PCA and enterotypes in the cohort. An instrumental principal
component analysis with the health status as instrumental vari-
able revealed that the microbial species abundance separated
patients and healthy controls (Fig. 1b, P¼ 1e 4, Monte Carlo
simulation). The genus Collinsella was enriched in patients
whereas Eubacterium and Roseburia and three species of Bac-
teroides were enriched in control subjects ((adjusted) adj.
Po0.05, Wilcoxon rank-sum test; Fig. 1c). Several bacterial
groups correlated with cardiovascular risk factors (Fig. 1d); in
particular, genera of Clostridiales, Clostridium sp. SS2/1 and the
poorly characterized butyrate-producing bacterium SSC/2 nega-
tively correlated with the inﬂammatory marker high-sensitivity
C-reactive protein (hsCRP; Fig. 1d and Supplementary Fig. S5).
A recent study suggests that the human gut microbiota can be
stratiﬁed into three enterotypes of distinct microbial composi-
tions13. We analysed our samples according to this earlier
study13, calculated the Jensen–Shannon distance of the genus
abundance and clustered samples with partitioning around
mediods. The Calinski–Harabasz index indicated that the
optimal number of clusters was three (Fig. 2a and
Supplementary Fig. S6). However, when the average silhouette
index was used to assess the quality of the clusters, we saw the
highest silhouette index with two clusters (Supplementary Figs
S6–7), which has also been observed previously15. We chose,
however, to use three clusters as proposed in the publication by
Arumugam et al.13, which is the largest enterotypes study to date.
The three enterotypes that we observed were characterized by the
same contributors at the genus level as shown previously13:
Bacteroides contributed to enterotype 1, Prevotella contributed to
entrotype 2 and Ruminococcus contributed to enterotype 3
(Fig. 2b and Supplementary Fig. S8). However, as described
previously13, the third enterotype may be identiﬁed by different
contributors depending on the source of sequence data and we
found this cluster to be characterized by low levels of Bacteroides
and Prevotella rather than a dominant genus (Supplementary Fig.
S8). To test whether the enterotypes were associated with disease
status, we used Fisher’s exact test and showed that patients were
underrepresented in enterotype 1 (P¼ 0.0048, Fisher’s exact test)
and overrepresented in enterotype 3 (P¼ 0.047, Fisher’s exact
test; Supplementary Table S1).
Metabolic functions of the gut microbiota. To discover new
genes in the metagenome, we performed de novo assembly of the
sequence data, ﬁrst for each individual sample separately and
subsequently for a pool of all the non-assembled data from the
individual samples to create one global gene catalog of our cohort.
A total of 1.7Gbp of contigs longer than 500 bp could be
assembled and with a N50 value of 1.8 kbp using 3 as coverage
cutoff and kmer of 31. MetaGeneMark16 was used to predict
genes from the contig set and 2.6 million open reading frames
representing 1.4 million non-redundant genes were found. The
genes were functionally annotated to KEGG, Pfam and
carbohydrate active enzyme (CAZy) databases and their relative
abundance was assessed. On average, 60% of the reads could be
aligned to the set of contigs, which is substantially more than the
percentage of reads (28%) that could be aligned to the reference
genomes. This indicates that our gene catalog contains a majority
of the sequenced microbiome.
A global analysis of the abundance of KEGG orthologies (KO)
resulted in separation of the patient group from the control group
(Supplementary Fig. S9). In total, 225 KOs were differentially
abundant (adj. Po0.05, Wilcoxon rank-sum test), illustrating
that there were functional aspects of the gut metagenome
associated with symptomatic atherosclerosis. Enriched
metabolic functions in the metagenomes of patients and
controls can be assessed by integrating the relative gene
abundance with metabolic networks. We used the reporter
feature algorithm17,18, and based on the KEGG metabolic
network and the pathway associations for the KOs together
with the corrected P-values, we identiﬁed ﬁrst, reporter pathways
(for example, pathways containing several signiﬁcantly
differentially abundant KOs; Supplementary Table S2) and
second reporter metabolites (for example, metabolites around
which there are enzymatic reactions with associated KO
differentially abundant; Supplementary Table S3).
The peptidoglycan biosynthesis pathway was the highest
scoring reporter pathway; eight peptidoglycan biosynthetic KOs
were enriched in the gut metagenomes of patients and one was
enriched in controls (adj. Po0.05, Wilcoxon rank-sum test,
Fig. 3a). Consequently, we also found several of the metabolites in
the peptidoglycan pathway to be reporter metabolites, for
example, UDP-N-acetyl-D-glucosamine, which is a key
precursor for peptidoglycan, indicating signiﬁcant changes in
KOs linked to these metabolites. There were also features of the
metagenome that correlated negatively with inﬂammation, the
highest scoring association being butyrate-acetoacetate CoA-
transferase (K01036) with hsCRP (Spearman’s r¼  0.73, adj.
P¼ 0.04). These ﬁndings are in agreement with a previous study
showing that butyrate is an important negative regulator of
inﬂammation19. To investigate the origin of the butyrate-
acetoacetate CoA-transferase genes, we performed a BLASTP
search and identiﬁed the source as Clostridium sp. SS2/1; as
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Figure 2 | Symptomatic atherosclerosis correlates with gut enterotypes.
(a) Three enterotypes in our cohort based on the abundance of genera.
Controls and patients are denoted by ﬁlled triangles and empty triangles,
respectively. Two subjects not included in the comparison are represented
by empty circles. Green is enterotype 1, red is enterotype 2 and blue is
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proposed drivers of the three enterotypes. Boxes denote the interquartile
range (IQR) between the ﬁrst and third quartiles and the line within denotes
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IQR from the ﬁrst and third quartiles, respectively. Circles denote data
points beyond the whiskers.
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discussed above, this species also negatively correlated with
hsCRP (Fig. 1d and Supplementary Fig. S5).
A recent metabolomics study showed that three microbially
modulated metabolites of dietary phosphatidylcholine
metabolism (choline, trimethylamine N-oxide and betaine)
correlate with CVD in humans11. We reconstructed the
metabolic pathway from phosphatidylcholine to trimethylamine
(Supplementary Fig. S10) but did not observe any signiﬁcant
association of gene abundance in this pathway with
atherosclerosis. However, we observed a positive correlation
between plasma triglycerides and the abundance of several KOs in
the pathway for fatty acid metabolism, speciﬁcally b-oxidation
(Fig. 3b, Supplementary Fig. S11), which suggests a strong
interaction between the gut microbiota and dietary components.
We also observed that the GS-GOGAT system, which the
microbiota uses for assimilation of nitrogen into amino acids, was
signiﬁcantly enriched in the patient group (Fig. 3c). In particular,
the ATP-dependent reaction carried out by glutamine synthase
(adj. P¼ 0.035, Wilcoxon rank-sum test) and the glutamate
synthase large and small subunits (adj. P¼ 0.013 and adj.
P¼ 0.0074, Wilcoxon rank-sum test, respectively) were enriched
in patient microbiota. The ATP-independent glutamate
dehydrogenase was not found to be different between the
groups.
Interestingly, phytoene dehydrogenase (K10027), which is
involved in the metabolism of lipid-soluble antioxidants (such
as the carotenoids lycopene and b-carotene), was the KO most
signiﬁcantly enriched in controls in our study (adj. P¼ 0.0046,
Wilcoxon rank-sum test, Fig. 4). To determine the phylogenetic
origin of the 13 genes annotated as phytoene dehydrogenases in
this study, we used BLASTP to search for related sequences in the
NCBI nr database. Seven of the genes matched to Bacteroides, two
to Clostridia, two to Prevotella and the remaining two to
Actinobacteria and various Bacteroidetes. We evaluated whether
the enrichment of phytoene dehydrogenase was accompanied by
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increased levels of carotenoids, and found increased levels of b-
carotene (P¼ 0.05, Student’s t-test), but not lycopene, in serum of
healthy controls compared with patients (Fig. 4, Supplementary
Figs S12–13).
Discussion
In this study, we identiﬁed several compositional and functional
alterations of the gut metagenome that may be related to
symptomatic atherosclerosis. The differences in the metagenome
between patients and controls did not seem to be related to
smoking, diabetes or body mass index (Supplementary Figs S14–
S19), but these factors and the potentially modifying effects of
different types of medication and diet that may be different
between patients and controls require further investigation.
Interestingly, we observed enrichment of patients within
the Ruminococcus enterotype.
The metagenomes of patients were enriched in genes associated
with peptidoglycan biosynthesis, which suggests that increased
peptidoglycan production by the gut metagenome may contribute
to symptomatic atherosclerosis by priming the innate immune
system and enhancing neutrophil function. Indeed, inﬂammation
has been identiﬁed as an important contributor to the pathogen-
esis of atherosclerosis20. The increased abundance of genes in this
pathway cannot be explained solely by a general increase in
Gram-positive bacteria because both Gram-positive and Gram-
negative bacteria have peptidoglycan and even more, abundant
Gram-positive groups of bacteria such as Eubacterium and
Roseburia were enriched in controls.
Our ﬁnding of enriched levels of phytoene dehydrogenase in
the metagenomes of healthy controls and its association with
elevated levels of b-carotene in the serum may indicate that the
possible production of this anti-oxidant by the gut microbiota
may have a positive health beneﬁt. Lycopene and b-carotene
adipose levels are associated with a reduced risk of CVD in
epidemiological studies21,22, but several large randomized,
placebo-controlled studies with durations up to 12 years have
failed to show that supplementation of pure b-carotene reduces
CVD risk23,24. However, lycopene has been related to intima-
media thickness of the common carotid artery25 and suggested to
have a role in the early stage and prevention of atherosclerosis26.
A previous study encompassing 4500 participants failed to
observe an association between lycopene intake and plasma
lycopene levels27, indicating that other mechanisms might be
more important in determining plasma levels than oral intake of
lycopene. Together with evidence that bacterial species from the
human gut can synthesize carotenoids28,29, we propose that our
ﬁndings of increased prevalence of phytoene dehydrogenase, and
increased levels of b-carotene in plasma of control subjects
represent an important step towards elucidating the importance
of carotenoids in the development of atherosclerosis. It is worth
noting that peptidoglycan and phytoene dehydrogenase genes
were not linked to obesity as there was no signiﬁcant difference in
abundance of these genes between lean and overweight/obese
subjects in our study (Supplementary Fig. S14), or in the meta-
analysis of an independent study13 (Supplementary Fig. S17).
In conclusion, here we observed associations between enter-
otypes, genera and species and symptomatic atherosclerosis at the
taxonomical level. Within the metagenome, genes in the
peptidoglycan pathway were enriched in patients, whereas genes
involved in synthesis of anti-inﬂammatory molecules (for
example, butyrate) and antioxidants were enriched in controls,
suggesting that the metagenome may contribute to the develop-
ment of symptomatic atherosclerosis by acting as a regulator of
host inﬂammatory pathways. Even though our study cannot
provide evidence for direct causal effects, these ﬁndings indicate
that the gut metagenome may have a role in the development of
symptomatic atherosclerosis.
Methods
Study design and recruitment. The patient samples were from the Go¨teborg
Atheroma Study Group Biobank, which includes samples from patients who had
undergone surgery to excise an atherosclerotic plaque30. The study was approved
by the Ethics Committee in Gothenburg. All subjects gave written informed
consent to participate after receiving oral and written information. All patients had
severely stenotic plaques in the carotid artery with ipsilateral manifestations of
emboli to either the brain, as minor brain infarction or transient ischemic
symptoms, or to the retinal artery (Table 1). The clinical deﬁnition of minor brain
infarction corresponds to a patient who has mild and no severe functional deﬁcits
without any need of prolonged hospital care. Hence, the underlying etiology in all
these patients was a vulnerable atherosclerotic plaque with plaque rupture and
embolism leading to operations with excision of the plaque30. It is not likely that
the clinical events per se directly inﬂuenced the gut metagenome, as minor stroke
has no acute effects on CRP and white blood cell count31 and because the patients
only had transient or minor tissue-damaging effects in the brain or eye.
The control group was selected to represent an age- and sex-matched group
with no cardiovascular health problems and was recruited from two on-going
population-based cohorts that have been described previously32,33. The
investigations of the control group included repeated ultrasound examinations of
the carotid and femoral arteries, and no large, potentially vulnerable plaques were
detected. Further inclusion criteria in the control group were no history of CVD,
no smoking, no diabetes and no treated hyperlipidemia. The underlying rationale
was to avoid subjects with vulnerable plaques deﬁned as echo-thin plaques with
stenosis 450% of vessel lumen34,35. Analysis of updated health records showed
that one control subject had a dilation of ascending aorta as the initial recruitment
as ‘healthy control’ and a second had white matter disease in the brain, possibly due
to a small artery disease. As these diagnoses may have atherosclerosis as underlying
cause, we excluded these subjects from analyses of differences between patients and
controls, although they were included in speciﬁed analyses of the total cohort.
Blood samples were drawn before surgery and plasma and serum samples were
prepared and immediately frozen at  70 1C. The subjects were given material and
instructions for providing fecal samples at home. Methods for processing fecal
samples and isolation of metagenomic DNA have been described previously36.
Sequencing. All samples were sequenced in the Illumina HiSeq2000 instrument
at SciLifeLab in Stockholm, Sweden, with up to ten samples pooled in one lane.
Libraries were prepared with a fragment length ofB300 bp. Paired-end reads were
generated with 100 bp in the forward and reverse direction.
Data quality control. Sequencing adapter sequences were removed with cutadapt
(http://code.google.com/p/cutadapt/). The length of each read was trimmed with
SolexaQA with the options ‘-b –p 0.05’37. Read pairs with either reads shorter than
35 bp were removed with a custom Python script. The high-quality reads were then
aligned to the human genome (NCBI version 37) with Bowtie38 using ‘-n 2 -l 35 -e
200 –best -p 8 –chunkmbs 1024 -X 600 –tryhard’. This set of high-quality
reads were then used for further analysis.
Alignment to reference genomes and taxonomical analysis. A set of 2,382
microbial reference genomes were obtained from the NCBI and Human Micro-
biome Project on 02 August 2011. The reference genomes were combined into two
Bowtie indexes and the metagenomic sequence reads were aligned to the reference
genomes using Bowtie with parameters ‘-n 2 -l 35 -e 200 –best -p 8 –chunkmbs
1024 -X 600 –tryhard’. Mapping results were merged by selecting the alignment
with fewest mismatches; if a read was aligned to a reference genome with the same
number of mismatches, each genome was assigned half to each genome. The
relative abundance of each genome was calculated by summing the number of
reads aligned to that genome divided by the genome size. In each subject, the
relative abundance was scaled to sum to one. The taxonomic rank for every gen-
ome was downloaded from NCBI taxonomy to assign each genome to a species,
genus and phyla. The relative abundance for each taxonomical rank was calculated
buy summing the relative abundance of all its members.
De novo assembly and gene calling. The high-quality reads were used for de novo
assembly with Velvet39 into contigs of at least 500-bp length using 3 as coverage
cutoff and kmer length of 31. To obtain long contigs with high speciﬁcity, we
iteratively explored parameter values for the kmer length and coverage cutoff to
balance the total assembly length and the N50 value to be used in the ﬁnal de novo
assembly. Reads from each subject were used in separate assemblies and
unassembled reads were then used in a global ﬁnal assembly. Genes were predicted
on the contigs with MetaGeneMark16. All genes were then aligned on the contigset
with Bowtie using the same parameters as above. The abundance of a gene was
calculated by counting the number of reads that align to the gene normalizing by
the gene length and the total number of reads aligned to any contig.
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Gene annotation. The genes were annotated to the KEGG database with hidden
Markov models (HMMs). Protein sequences for microbial orthologs were down-
loaded and aligned with MUSCLE40. HMMs were generated with HMMer3
(ref. 41) for each KO. Each gene was queried on the 4,283 HMMs and annotated
the KO with lowest scoring E-value below 10 20. Out of the 2,645,414 genes,
848,353 (32%) were annotated to KOs. The genes were also annotated to CAZy42.
The CAZy proteins of bacterial and archaeal origin were downloaded and HMMs
were built and genes annotated as described above. The feature abundance (KOs
and CAZy) was calculated by summing the abundance of genes annotated to a feature.
Genes for betaine reductase were collected from two species, Clostridium difﬁcile 630
(Entrez protein accession codes Gi: 126699967 and GI: 126699969) and
Carboxydothermus hydrogenoformans Z-2901 (Entrez protein accession codes
Gi: 78044558 and GI: 78044225). The gene catalogue was searched against these four
genes with USEARCH43 using an E-value cutoff of 10 30.
Statistical analysis. To determine differential abundance of metagenomic features
(that is, taxonomic and functional features between patients and controls) Wil-
coxon rank-sum test was applied. Strains and genera with a relative abundance in
any subject above 10 5 and 10 3, respectively, were included in the analysis.
Correlations were done between serum biomarkers and metagenomic features with
Spearman’s correlation. P-values were adjusted with false discovery rate with the
method from Benjamini and Hochberg44 when multiple hypotheses were
considered simultaneously and are denoted adj. P. The R package ade4 using
instrumental principal component analysis45 was used to determine the global
analysis of species abundance between patients and controls (in Fig. 1b and
Supplementary Figs S7,S9,S18,S19). Monte Carlo test on the between-groups
inertia percentage was performed 10,000 permutations to calculate a P-value
in Fig. 1b.
Testing the association between microbial genes and obesity. We analysed
data from Arumugam et al.13 to investigate whether the abundance of
peptidoglycan and phytoene dehydrogenase genes in the gut metagenome differed
between obese and lean subjects. The corresponding clusters of orthologous groups
was identiﬁed to the KOs involved in peptidoglycan biosynthesis and phytoene
dehydrogenase. The results are presented in Supplementary Figs S14–S17. There
was no signiﬁcant differential abundance of the studied corresponding clusters of
orthologous groups between healthy lean and obese subjects (Wilcoxon rank-sum
test).
Measurement of b-carotene and lycopene. b-Carotene and lycopene were
measured in the serum from healthy controls and patients using a modiﬁed pro-
tocol from46. Brieﬂy, 200ml of serum was mixed with 200 ml of ethanol and 8 ml of
0.191mmol l 1 retinyl propionate in ethanol. Samples were vortexed gently and
then 1ml hexane was added; the samples were again vortexed (for 30 s). The phases
were separated by centrifugation at 1,500g for 5min and 900 ml of the upper phase
was then transferred to a new tube. The samples were dried under low pressure at
room temperature in a Speedvac concentrator, not to complete dryness. The
residue was dissolved in 100ml ethanol followed by addition of 100 ml acetonitrile.
Samples were protected from light during handling and preparation.
The compounds were measured using a Dionex HPLC system with a C18
column, maintained at 29 1C. The mobile phase was ethanol and acetonitrile (1:1)
with 0.1ml l 1 diethylamine and was kept at a ﬂow rate of 0.9mlmin 1. Samples
were stored at 4 1C before injection of 50 ml. Chromatograms for absorbance at the
wavelengths 300, 325 and 450 nm were collected simultaneously for 20min. Peaks
were identiﬁed by comparing retention time with a standard solution of b-carotene
and lycopene. Quantiﬁcation was based on the area under the curve.
References
1. Ba¨ckhed, F., Ley, R. E., Sonnenburg, J. L., Peterson, D. A. & Gordon, J. I.
Host-bacterial mutualism in the human intestine. Science 307, 1915–1920
(2005).
2. Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance.
Diabetes 56, 1761–1772 (2007).
3. Ba¨ckhed, F. et al. The gut microbiota as an environmental factor that regulates
fat storage. Proc. Natl Acad. Sci. USA 101, 15718–15723 (2004).
4. Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human
gut microbes associated with obesity. Nature 444, 1022–1023 (2006).
5. Erridge, C., Attina, T., Spickett, C. M. & Webb, D. J. A high-fat meal induces
low-grade endotoxemia: evidence of a novel mechanism of postprandial
inﬂammation. Am. J. Clin. Nutr. 86, 1286–1292 (2007).
6. Schertzer, J. D. et al. NOD1 activators link innate immunity to insulin
resistance. Diabetes 60, 2206–2215 (2011).
7. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic
sequencing. Nature 464, 59–65 (2010).
8. Human Microbiome Project Consortium. Structure, function and diversity
of the healthy human microbiome. Nature 486, 207–214 (2012).
9. Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins.
Nature 457, 480–484 (2009).
10. Greenblum, S., Turnbaugh, P. J. & Borenstein, E. Metagenomic systems biology of
the human gut microbiome reveals topological shifts associated with obesity and
inﬂammatory bowel disease. Proc. Natl Acad. Sci. USA 109, 594–599 (2012).
11. Wang, Z. et al. Gut ﬂora metabolism of phosphatidylcholine promotes
cardiovascular disease. Nature 472, 57–63 (2011).
12. Koren, O. et al. Human oral, gut, and plaque microbiota in patients with
atherosclerosis. Proc. Natl Acad. Sci. USA 108(Suppl 1): 4592–4598 (2011).
13. Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473,
174–180 (2011).
14. Tap, J. et al. Towards the human intestinal microbiota phylogenetic core.
Environ. Microbiol. 11, 2574–2584 (2009).
15. Wu, G. D. et al. Linking long-term dietary patterns with gut microbial
enterotypes. Science 334, 105–8 (2011).
16. Zhu, W., Lomsadze, A. & Borodovsky, M. Ab initio gene identiﬁcation in
metagenomic sequences. Nucleic Acids Res. 38, e132 (2010).
17. Oliveira, A. P., Patil, K. R. & Nielsen, J. Architecture of transcriptional
regulatory circuits is knitted over the topology of bio-molecular interaction
networks. BMC Syst. Biol. 2, 17 (2008).
18. Patil, K. R. & Nielsen, J. Uncovering transcriptional regulation of metabolism by using
metabolic network topology. Proc. Natl Acad. Sci. USA 102, 2685–2689 (2005).
19. Maslowski, K. M. et al. Regulation of inﬂammatory responses by gut microbiota
and chemoattractant receptor GPR43. Nature 461, 1282–1286 (2009).
20. Hansson, G. K. Inﬂammation, atherosclerosis, and coronary artery disease.
N. Engl. J. Med. 352, 1685–1695 (2005).
21. Kardinaal, A. F. et al. Antioxidants in adipose tissue and risk of myocardial
infarction: the EURAMIC Study. Lancet 342, 1379–1384 (1993).
22. Kohlmeier, L. et al. Lycopene and myocardial infarction risk in the
EURAMIC study. Am. J. Epidemiol. 146, 618–626 (1997).
23. Hennekens, C. H. et al. Lack of effect of long-term supplementation with beta
carotene on the incidence of malignant neoplasms and cardiovascular disease.
N. Engl. J. Med. 334, 1145–1149 (1996).
24. Kritchevsky, S. B. beta-Carotene, carotenoids and the prevention of coronary
heart disease. J. Nutr. 129, 5–8 (1999).
25. Rissanen, T. H. et al. Serum lycopene concentrations and carotid
atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study.
Am. J. Clin. Nutr. 77, 133–138 (2003).
26. Sesso, H. D., Buring, J. E., Norkus, E. P. & Gaziano, J. M. Plasma lycopene,
other carotenoids, and retinol and the risk of cardiovascular disease in women.
Am. J. Clin. Nutr. 79, 47–53 (2004).
27. Bermudez, O. I., Ribaya-Mercado, J. D., Talegawkar, S. A. & Tucker, K. L.
Hispanic and non-Hispanic white elders from Massachusetts have different
patterns of carotenoid intake and plasma concentrations. J. Nutr. 135,
1496–1502 (2005).
28. Khaneja, R. et al. Carotenoids found in Bacillus. J. Appl. Microbiol. 108,
1889–1902 (2010).
29. Perez-Fons, L. et al. Identiﬁcation and the developmental formation of
carotenoid pigments in the yellow/orange Bacillus spore-formers. Biochim.
Biophys. Acta 1811, 177–185 (2011).
30. Fagerberg, B. et al. Differences in lesion severity and cellular composition
between in vivo assessed upstream and downstream sides of human
symptomatic carotid atherosclerotic plaques. J. Vasc. Res. 47, 221–230 (2010).
31. Christensen, H. & Boysen, G. C-reactive protein and white blood cell count increases
in the ﬁrst 24hours after acute stroke. Cerebrovasc. Dis. 18, 214–219 (2004).
32. Fagerberg, B., Kellis, D., Bergstrom, G. & Behre, C. J. Adiponectin in relation
to insulin sensitivity and insulin secretion in the development of type 2
diabetes: a prospective study in 64-year-old women. J. Intern. Med. 269,
636–643 (2011).
33. Schmidt, C. & Wikstrand, J. High apoB/apoA-I ratio is associated with
increased progression rate of carotid artery intima-media thickness in clinically
healthy 58-year-old men: experiences from very long-term follow-up in the AIR
study. Atherosclerosis 205, 284–289 (2009).
34. Mathiesen, E. B., Bonaa, K. H. & Joakimsen, O. Echolucent plaques are
associated with high risk of ischemic cerebrovascular events in carotid stenosis:
the tromso study. Circulation 103, 2171–2175 (2001).
35. Prahl, U. et al. Percentage white: a new feature for ultrasound classiﬁcation of
plaque echogenicity in carotid artery atherosclerosis. Ultrasound Med. Biol. 36,
218–226 (2010).
36. Salonen, A. et al. Comparative analysis of fecal DNA extraction methods with
phylogenetic microarray: effective recovery of bacterial and archaeal DNA
using mechanical cell lysis. J. Microbiol. Methods 81, 127–134 (2010).
37. Cox, M. P., Peterson, D. A. & Biggs, P. J. SolexaQA: At-a-glance quality
assessment of Illumina second-generation sequencing data. BMC
Bioinformatics 11, 485 (2010).
38. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-
efﬁcient alignment of short DNA sequences to the human genome. Genome
Biol. 10, R25 (2009).
39. Zerbino, D. R. & Birney, E. Velvet: algorithms for de novo short read assembly
using de Bruijn graphs. Genome Res. 18, 821–829 (2008).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2266 ARTICLE
NATURE COMMUNICATIONS | 3:1245 |DOI: 10.1038/ncomms2266 | www.nature.com/naturecommunications 7
& 2012 Macmillan Publishers Limited. All rights reserved.
40. Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and
high throughput. Nucleic Acids Res. 32, 1792–1797 (2004).
41. Eddy, S. R. Proﬁle hidden Markov models. Bioinformatics 14, 755–763 (1998).
42. Cantarel, B. L. et al. The carbohydrate-active EnZymes database (CAZy): an
expert resource for glycogenomics. Nucleic Acids Res. 37, D233–238 (2009).
43. Edgar, R. C. Search and clustering orders of magnitude faster than BLAST.
Bioinformatics 26, 2460–2461 (2010).
44. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate—a practical and
powerful approach to multiple testing. J. Roy. Stat. Soc. B Met. 57, 289–300 (1995).
45. Dray, S. & Dufour, A. B. The ade4 package: Implementing the duality diagram
for ecologists. J. Stat. Softw. 22, 1–20 (2007).
46. Sowell, A. L., Huff, D. L., Yeager, P. R., Caudill, S. P. & Gunter, E. W.
Retinol, alpha-tocopherol, lutein/zeaxanthin, beta-cryptoxanthin, lycopene,
alpha-carotene, trans-beta-carotene, and four retinyl esters in serum
determined simultaneously by reversed-phase HPLC with multiwavelength
detection. Clin. Chem. 40, 411–416 (1994).
Acknowledgements
We acknowledge Rosie Perkins for critically reading and editing the manuscript,
Suwanee Jansa-Ard for technical assistance with HPLC measurements, Swedish National
Infrastructure for large-scale sequencing for performing the Illumina sequencing and our
colleagues of the Go¨teborg Atheroma Study Group (Sahlgrenska University Hospital and
University of Gothenburg) and Marie Louise Ekholm for providing clinical specimens.
The bioinformatic computations were performed on resources provided by the Swedish
National Infrastructure for Computing (SNIC) at C3SE. This study was funded by Knut and
Alice Wallenberg Foundation, the Chalmers Foundation, Swedish Heart Lung Foundation,
Torsten So¨derberg’s Foundation, IngaBritt och Arne Lundbergs foundation, AFA Insurances,
the Swedish Research Council and the Swedish Foundation for Strategic Research.
Author contributions
J.N., F.B., D.P. and B.F. conceived and designed the project. F.H.K., F.F., and V.T.,
performed the experiments. F.H.K. and I.N. analysed the sequence data. All authors
contributed writing and editing the manuscript. F.B. and J.N. contributed equally to the
study.
Additional information
Accession codes: Gut metagenome sequences have been deposited in the Sequence Read
Archive under accession code SRA059451.
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: J.N and F.B. are shareholders in MetaboGen AB. All
other authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Karlsson F. H. et al. Symptomatic atherosclerosis is associated
with an altered gut metagenome. Nat. Commun. 3:1245 doi: 10.1038/ncomms2266 (2012).
This work is licensed under a Creative Commons Attribution-
NonCommercial-No Derivative Works 3.0 Unported License. To view
a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2266
8 NATURE COMMUNICATIONS | 3:1245 | DOI: 10.1038/ncomms2266 | www.nature.com/naturecommunications
& 2012 Macmillan Publishers Limited. All rights reserved.
